TNF-alpha Antibody - #BF0170

(3)   (4)  
製品: TNF-alpha Antibody
カタログ: BF0170
タンパク質の説明: Mouse monoclonal antibody to TNF-alpha
アプリケーション: WB ELISA
Cited expt.: WB
反応性: Human
分子量: 17kDa(Observed); 26kD(Calculated).
ユニプロット: P01375
RRID: AB_2833613

類似製品を見る>>

   サイズ 価格 在庫状況
 50ul $250 在庫あり
 100ul $350 在庫あり
 200ul $450 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Mouse
アプリケーション:
ELISA 1:10000, WB 1:500-1:2000
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human
クローナリティ:
Monoclonal [AFB1588]
特異性:
TNF-alpha antibody detects endogenous levels of total TNF-alpha.
RRID:
AB_2833613
引用形式: Affinity Biosciences Cat# BF0170, RRID:AB_2833613.
コンジュゲート:
Unconjugated.
精製:
Affinity-chromatography.
保存:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

APC1; APC1 protein; Cachectin; DIF; Differentiation inducing factor; Macrophage cytotoxic factor; Tnf; TNF superfamily, member 2; TNF, macrophage derived; TNF, monocyte derived; TNF-a; TNF-alpha; TNFA; TNFA_HUMAN; TNFSF2; Tumor necrosis factor alpha; Tumor necrosis factor; Tumor necrosis factor ligand superfamily member 2; Tumor Necrosis Factor, Membrane Form; Tumor necrosis factor, soluble form;

免疫原

免疫原:

Purified recombinant fragment of human TNF-alpha expressed in E. Coli.

Uniprot:

P01375(TNFA_HUMAN) >>Visit HPA database.

遺伝子(ID):
TNF(7124)
タンパク質の説明:
TNF-alpha (tumor necrosis factor alpha) is an important cytokine produced by numerous cell types including neutrophils, activated lymphocytes, macrophages and NK cells. It plays a critical role in inflammatory responses and in apoptosis. TNF-alpha is believed to mediate pathogenic shock and tissue injury associated with endotoxemia. TNF-alpha exists as a multimer of two, three, or five non covalently linked units, but shows a single 17 kDa band following SDS PAGE under non reducing conditions. Although it has little effect on many cultured normal human cells, TNF-alpha appears to be directly toxic to vascular endothelial cells. Other actions of TNF-alpha include stimulating growth of human fibroblasts and other cell lines, activating polymorphonuclear neutrophils and osteoclasts, and induction of interleukin 1, prostaglandin E2 and collagenase production. TNF-alpha is currently being evaluated in treatment of certain cancers and AIDS Related Complex.
タンパク質配列:
MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL

研究背景

機能:

Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity).

The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.

PTMs:

The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form is further proteolytically processed by SPPL2A or SPPL2B through regulated intramembrane proteolysis producing TNF intracellular domains (ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.

The membrane form, but not the soluble form, is phosphorylated on serine residues. Dephosphorylation of the membrane form occurs by binding to soluble TNFRSF1A/TNFR1.

O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.

細胞の位置付け:

Cell membrane>Single-pass type II membrane protein.

Membrane>Single-pass type II membrane protein.

Secreted.

Secreted.

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
タンパク質ファミリー:

Belongs to the tumor necrosis factor family.

研究領域

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Antifolate resistance.

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Endocrine and metabolic diseases > Type I diabetes mellitus.

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > African trypanosomiasis.

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Immune diseases > Asthma.

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Human Diseases > Immune diseases > Systemic lupus erythematosus.

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Human Diseases > Immune diseases > Allograft rejection.

· Human Diseases > Immune diseases > Graft-versus-host disease.

· Human Diseases > Cardiovascular diseases > Hypertrophic cardiomyopathy (HCM).

· Human Diseases > Cardiovascular diseases > Dilated cardiomyopathy (DCM).

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Antigen processing and presentation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Hematopoietic cell lineage.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

参考文献

1). The novel hyaluronic acid granular hydrogel attenuates osteoarthritis progression by inhibiting the TLR-2/NF-κB signaling pathway through suppressing cellular senescence. Bioengineering & Translational Medicine, 2023 (PubMed: 37206234) [IF=7.4]

Application: IF/ICC    Species: Human    Sample:

FIGURE 3 (a) Cell viability of chondrocytes after incubation with different concentrations of ARTZ® and novel HA (n‐HA) using the CCK‐8 assay. (b) Cell proliferation measurement of chondrocytes after incubation with 1 mg/ml ARTZ® and n‐HA for 1, 2, and 3 days using CCK‐8 assay. (c) Live/Dead staining of chondrocytes after incubation with 1 mg/ml ARTZ® and n‐HA for 1, 2, and 3 days, the live cells were stained green, whereas the dead cells were stained red. Scale bar = 200 μm. (d) Representative confocal images of phalloidin stained chondrocytes with or without TNF‐α, ARTZ®, and n‐HA treatment. Scale bar = 100 μm. (e) The quantification of apoptotic rates of chondrocytes with various treatment by flow cytometry. (n = 3, *p 
2). Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs. European Journal of Pharmacology, 2020 (PubMed: 31747547) [IF=4.2]

Application: WB    Species: Human    Sample: HUVECs

Fig. S1. Effect of a RAGE receptor inhibitor (FPS-ZM1) on cell viability, pro-inflammatory gene expression, cell apoptosis and reactive oxygen species production. The HUVECs in the experiment were divided into four groups: control, AGEs (200 µg/mL), AGEs+Sal (50 µM), and AGEs+FPS-ZM1 (1 µg/ml, 1 h). (A) Cell viability of HUVECs. (B-D) Expression of pro-inflammatory genes (B: TNF-a; C: IL-1β; D: IL-6). (E) Representative cell apoptosis images were after Hoechst 33342 staining. (F) Representative images of reactive oxygen species induced fluorescence signals. The data are representative of one experiment performed in triplicate and are expressed as the mean ± S.D. **P<0.01 vs. control group; ##P<0.01 vs. AGEs group.
3). Inflammation Is More Sensitive than Cell Proliferation in Response to Rapamycin Treatment in Polycystic Kidney Disease. Kidney & blood pressure research, 2024 (PubMed: 38167222) [IF=2.8]

Application: WB    Species: Rat    Sample:

Fig. 3. mTOR cell signaling pathways and pro-inflammatory factors in rapamycin (Rap) or vehicle-treated cystic kidneys. a The inhibition of the mTOR pathway (p-p70S6K) and the feedback activation of Akt (p-Akt) were analyzed by Western blot in 12-week-old +/+ and Cy/+ kidneys (6 rats in each group). b The expression of CFB, TNF-α, and MCP-1 was analyzed by Western blot in 12-week-old +/+ and Cy/+ kidneys. Blots are representative of three independent experiments. c Western blot expression quantified by densitometry, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.